

# Juan Fortea

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3037161/publications.pdf>

Version: 2024-02-01

235  
papers

12,218  
citations

39113

52  
h-index

40945

97  
g-index

256  
all docs

256  
docs citations

256  
times ranked

15128  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis. <i>Journal of Neurology</i> , 2022, 269, 1427-1438.	1.8	9
2	Fluid biomarkers for Alzheimer's disease in Down syndrome: Current status and novel trends. , 2022, , 97-128.		0
3	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. <i>Brain</i> , 2022, 145, 1757-1762.	3.7	17
4	Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	1
5	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
6	The A $\beta$ 1-42/A $\beta$ 1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than A $\beta$ 1-42 alone. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 20.	3.0	18
7	Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders. <i>Cell Metabolism</i> , 2022, 34, 269-284.e9.	7.2	13
8	Cortical microstructure in primary progressive aphasia: a multicenter study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 27.	3.0	10
9	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. <i>Alzheimer's and Dementia</i> , 2022, 18, 1957-1968.	0.4	2
10	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. <i>Journal of Neural Transmission</i> , 2022, 129, 231-237.	1.4	7
11	Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. <i>Journal of Neurodevelopmental Disorders</i> , 2022, 14, 22.	1.5	13
12	The crucial history of Down syndrome. <i>Lancet Neurology</i> , The, 2022, 21, 222.	4.9	0
13	Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, 838412.	1.4	1
14	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. <i>Molecular Neurodegeneration</i> , 2022, 17, 29.	4.4	7
15	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
16	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
17	Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4307.	1.8	14
18	Cerebral Amyloid Angiopathy-Related Inflammation in Down Syndrome-Related Alzheimer Disease. <i>Neurology</i> , 2022, , 10.1212/WNL.0000000000200704.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>JAMA Network Open</i> , 2022, 5, e229588.	2.8	18
20	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. <i>JAMA Network Open</i> , 2022, 5, e2212910.	2.8	47
21	DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients. <i>Biomedicines</i> , 2022, 10, 1380.	1.4	2
22	Myelin loss in <i>C9orf72</i> hexanucleotide expansion carriers. <i>Journal of Neuroscience Research</i> , 2022, 100, 1862-1875.	1.3	4
23	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 618-628.	0.4	27
24	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. <i>Alzheimer's and Dementia</i> , 2021, 17, 605-617.	0.4	17
25	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 163-175.	1.2	5
26	Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 671-681.	1.2	23
27	Multilingualism in semantic dementia: language-dependent lexical retrieval from degraded conceptual representations. <i>Aphasiology</i> , 2021, 35, 240-266.	1.4	7
28	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	9.4	198
29	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, 1329-1341.	0.4	34
30	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. <i>JAMA Network Open</i> , 2021, 4, e211290.	2.8	12
31	Opportunities, barriers, and recommendations in Down syndrome research. <i>Translational Science of Rare Diseases</i> , 2021, 5, 99-129.	1.6	33
32	AMYQ: An index to standardize quantitative amyloid load across PET tracers. <i>Alzheimer's and Dementia</i> , 2021, 17, 1499-1508.	0.4	11
33	Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid positivity. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1037-1049.	1.3	6
34	Atypical astroglial pTDP43 pathology in astroglial predominant tauopathy. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 1109-1113.	1.8	5
35	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
36	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	0.9	30

#	ARTICLE	IF	CITATIONS
37	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 119.	3.0	6
38	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation <sup>1</sup> . <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1505-1527.	1.2	14
39	Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity. <i>Journal of Clinical Medicine</i> , 2021, 10, 2776.	1.0	43
40	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	5.8	33
41	Sleep Disorders in Adults with Down Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3012.	1.0	12
42	Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients. <i>Scientific Reports</i> , 2021, 11, 16805.	1.6	17
43	Small Neuron-Derived Extracellular Vesicles from Individuals with Down Syndrome Propagate Tau Pathology in the Wildtype Mouse Brain. <i>Journal of Clinical Medicine</i> , 2021, 10, 3931.	1.0	10
44	Association of Apolipoprotein E $\epsilon$ 4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021, 78, 937.	4.5	32
45	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , 2021, 90, 407-416.	2.8	7
46	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. <i>Lancet Neurology</i> , The, 2021, 20, 605-614.	4.9	29
47	Association of cortical microstructure with amyloid- $\beta$ and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. <i>Molecular Psychiatry</i> , 2021, 26, 7813-7822.	4.1	17
48	Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12184.	1.2	10
49	Accelerated long-term forgetting over three months in asymptomatic APOE $\epsilon$ 4 carriers. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 477-484.	1.7	7
50	The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 4582.	1.0	9
51	Alzheimer's disease associated with Down syndrome: a genetic form of dementia. <i>Lancet Neurology</i> , The, 2021, 20, 930-942.	4.9	93
52	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. <i>Frontiers in Neurology</i> , 2021, 12, 750543.	1.1	6
53	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	4
54	Late-onset epileptic seizures in adults with Down syndrome are linked to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
55	Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
56	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. <i>Translational Neurodegeneration</i> , 2021, 10, 50.	3.6	32
57	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
58	Calsyntenin1 is a cerebrospinal fluid marker of frontotemporal dementia-related synapse degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
59	Cortical microinfarcts along the Alzheimer's disease continuum in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
60	Neuropsychological correlates of plasma NfL in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
61	Alzheimer's disease clinical onset and age at death in people with Down syndrome: A systematic review and population-based study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
62	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
63	Transcriptome-wide characterization of the frontal cortex in FTLD.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e049569.	0.4	0
64	Detection of amyloid beta peptides in body fluids for the diagnosis of Alzheimer's disease: Where do we stand?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 99-113.	2.7	24
65	Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. <i>Cerebral Cortex</i> , 2020, 30, 2083-2098.	1.6	25
66	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	54
67	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12052.	1.2	7
68	Cortical microstructure in the amyotrophic lateral sclerosis–frontotemporal dementia continuum. <i>Neurology</i> , 2020, 95, e2565-e2576.	1.5	19
69	Evaluation of biochemical and hematological parameters in adults with Down syndrome. <i>Scientific Reports</i> , 2020, 10, 13755.	1.6	4
70	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , 2020, 15, 46.	4.4	21
71	AmyQ: An index to accurately measure cerebral amyloid load. <i>Alzheimer's and Dementia</i> , 2020, 16, e039735.	0.4	0
72	Oligodendroglial alterations in FTD caused by C9orf72 expansion. <i>Alzheimer's and Dementia</i> , 2020, 16, e040196.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Cerebrospinal fluid neuroinflammatory biomarkers along the Alzheimer disease continuum in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e041255.	0.4	0
74	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. <i>Alzheimer's and Dementia</i> , 2020, 16, e041500.	0.4	0
75	The relationship between cortical microstructural changes and in vivo amyloid $\beta$ and tau in aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041626.	0.4	0
76	Transcriptome characterization of the motor cortex suggests microglial-related key events due to TDP $\beta$ 43 aberrant inclusions. <i>Alzheimer's and Dementia</i> , 2020, 16, e042953.	0.4	0
77	1 H $\beta$ MRS signature in Alzheimer disease in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e043346.	0.4	0
78	Domiciliary Alzheimer visiting in Down syndrome pilot project: Preliminary results. <i>Alzheimer's and Dementia</i> , 2020, 16, e043491.	0.4	0
79	Longitudinal plasma levels of neurofilament light in Down syndrome: A multicenter study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044772.	0.4	0
80	VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045268.	0.4	0
81	Biomarkers and trial-ready cohorts for Alzheimer's disease clinical trials in the Down syndrome population. <i>Alzheimer's and Dementia</i> , 2020, 16, e046943.	0.4	0
82	Blood-based detection of early-stage Alzheimer using multiomics and machine learning. <i>Alzheimer's and Dementia</i> , 2020, 16, e047334.	0.4	0
83	Periodontal disease as a possible cause for Alzheimer's disease. <i>Periodontology 2000</i> , 2020, 83, 242-271.	6.3	76
84	Annexin A5 prevents amyloid $\beta$ -induced toxicity in choroid plexus: implication for Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 9391.	1.6	18
85	Further understanding the connection between Alzheimer's disease and Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, 1065-1077.	0.4	52
86	Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12047.	1.2	25
87	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet, The</i> , 2020, 395, 1988-1997.	6.3	164
88	COVID-19-associated ophthalmoparesis and hypothalamic involvement. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	3.1	62
89	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1585-1595.	1.2	25
90	Cortical microstructural correlates of astrogliosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , 2020, 94, e2026-e2036.	1.5	42

#	ARTICLE	IF	CITATIONS
91	Distinctive Oculomotor Behaviors in Alzheimer's Disease and Frontotemporal Dementia. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 603790.	1.7	17
92	The AT(N) framework for Alzheimer's disease in adults with Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12062.	1.2	12
93	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. <i>Nature Neuroscience</i> , 2019, 22, 1258-1268.	7.1	48
94	Exosome release and cargo in Down syndrome. <i>Developmental Neurobiology</i> , 2019, 79, 639-655.	1.5	15
95	Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. <i>Developmental Neurobiology</i> , 2019, 79, 716-737.	1.5	30
96	Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. <i>Nature Communications</i> , 2019, 10, 4766.	5.8	73
97	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 597-609.	1.8	44
98	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1815-1824.	1.7	104
99	Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1333-1347.	0.4	111
100	Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review. <i>Journal of Neurodevelopmental Disorders</i> , 2019, 11, 20.	1.5	26
101	A nonsynonymous mutation in <i>PLCG2</i> reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	3.9	87
102	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 7803.	1.6	33
103	Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 211-225.	1.2	10
104	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , 2019, 142, 1121-1133.	3.7	45
105	Nanoscale structure of amyloid- $\beta^2$ plaques in Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 5181.	1.6	52
106	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.4	82
107	ICP148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P119.	0.4	0
108	O201: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P558.	0.4	0

#	ARTICLE	IF	CITATIONS
109	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2518-2530.	1.7	13
110	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.4	310
111	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 546-560.	2.5	115
112	Elevated YKL-40 and low sAPP $\beta$ :YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTL. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 180-186.	0.9	17
113	The Intersection of Intellectual Disability and Dementia: Report of The International Summit on Intellectual Disability and Dementia. <i>Gerontologist</i> , 2019, 59, 411-419.	2.3	8
114	Challenges associated with biomarker-based classification systems for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 346-357.	1.2	37
115	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 64, 58-67.	1.5	8
116	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
117	Cortical microstructural changes along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2018, 14, 340-351.	0.4	122
118	Consensus statement of the international summit on intellectual disability and Dementia related to post-diagnostic support. <i>Aging and Mental Health</i> , 2018, 22, 1406-1415.	1.5	18
119	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the <i>C9orf72</i> expansion mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 162-168.	0.9	44
120	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
121	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 99-111.	1.2	9
122	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. <i>Neurobiology of Aging</i> , 2018, 62, 245.e1-245.e7.	1.5	16
123	P4076: CEREBROSPINAL FLUID CORE BIOMARKERS ALLOW AN ACCURATE DIAGNOSIS OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2018, 14, P1463.	0.4	0
124	Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 1725-1733.	1.4	56
125	P2262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P777.	0.4	0
126	O50401: A RARE GENETIC VARIANT IN THE <i>PLCG2</i> GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1648.	0.4	0



#	ARTICLE	IF	CITATIONS
127	P1â€277: CORRELATION BETWEEN INNOTESTÂ® AND THE FULLY AUTOMATED LUMIPULSEÂ® G PLATFORM FOR THE ANALYSIS OF Î²â€AMYLOID 1â€42 AND TOTAL TAU. <i>Alzheimer's and Dementia</i> , 2018, 14, P388.	0.4	1
128	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 703-713.	1.8	63
129	CSF sAPPÎ², YKL-40, and NfL along the ALS-FTD spectrum. <i>Neurology</i> , 2018, 91, e1619-e1628.	1.5	59
130	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	2.8	132
131	P1â€293: IDENTIFICATION OF EXOSOMAL MICRORNAs AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P398.	0.4	0
132	P2â€230: CHALLENGES ASSOCIATED WITH BIOMARKERâ€BASED CLASSIFICATIONS SYSTEMS FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P756.	0.4	0
133	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of AÎ² species. <i>NeuroImage: Clinical</i> , 2018, 20, 603-610.	1.4	11
134	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet Neurology</i> , The, 2018, 17, 860-869.	4.9	140
135	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients â€ An Atlas-Based Volumetric MRI Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 45.	1.7	40
136	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 797-819.	1.2	38
137	Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimerâ€™s Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 609.	1.4	59
138	Quality Care for People with Intellectual Disability and Advanced Dementia: Guidance on Service Provision. <i>Journal of Palliative Medicine</i> , 2018, 21, 1344-1352.	0.6	7
139	Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA. <i>Cortex</i> , 2018, 108, 252-264.	1.1	41
140	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 505-513.	1.2	16
141	The nonlinear relationship between cerebrospinal fluid AÎ²42 and tau in preclinical Alzheimerâ€™s disease. <i>PLoS ONE</i> , 2018, 13, e0191240.	1.1	41
142	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. <i>Oncotarget</i> , 2018, 9, 34691-34698.	0.8	57
143	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimerâ€™s Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1065-1074.	1.2	5
144	Consensus statement of the International Summit on Intellectual Disability and Dementia related to endâ€ofâ€life care in advanced dementia. <i>Journal of Applied Research in Intellectual Disabilities</i> , 2017, 30, 1160-1164.	1.3	35

#	ARTICLE	IF	CITATIONS
145	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1251-1260.	0.4	47
146	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2017, 134, 475-487.	3.9	53
147	Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 909-918.	1.2	28
148	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017, 7, 2477.	1.6	28
149	CSF sAPP $\beta$ , YKL-40, and neurofilament light in frontotemporal lobar degeneration. <i>Neurology</i> , 2017, 89, 178-188.	1.5	100
150	Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 855-870.	1.2	14
151	Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 1-10.	1.2	28
152	Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1471-1476.	2.8	161
153	Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. <i>Neurobiology of Aging</i> , 2017, 53, 192.e1-192.e4.	1.5	24
154	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
155	[P1366]: WEIGHT LOSS MIGHT BE A NON-COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P399.	0.4	0
156	[P3274]: STRUCTURAL CORRELATES OF ALZHEIMER'S DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1048.	0.4	0
157	The pitfalls of biomarker-based classification schemes. <i>Alzheimer's and Dementia</i> , 2017, 13, 1072-1074.	0.4	5
158	YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. <i>Journal of Neuroinflammation</i> , 2017, 14, 118.	3.1	99
159	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , 2017, 54, 6647-6654.	1.9	45
160	Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome. <i>Alzheimer's and Dementia</i> , 2017, 13, 541-549.	0.4	94
161	Longitudinal brain structural changes in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 499-509.	0.4	65
162	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. <i>Molecular Neurobiology</i> , 2017, 54, 5550-5562.	1.9	119

#	ARTICLE	IF	CITATIONS
163	[P1â€“238]: THE SAPPÎ <sup>2</sup> /YKLâ€“40 RATIO IN CEREBROSPINAL FLUID AS A DIAGNOSTIC MARKER IN FRONTOTEMPORAL LOBAR DEGENERATION: A PATHOLOGICAL STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P335.	0.4	0
164	[P2â€“259]: NETWORK ANALYSIS OF THE CSF PROTEOME IDENTIFIES SYNAPTIC PROTEINS OF HIPPOCAMPAL ORIGIN AS PUTATIVE BIOMARKERS FOR ADâ€“RELATED SYNAPSE LOSS. <i>Alzheimer's and Dementia</i> , 2017, 13, P712.	0.4	0
165	[O3â€“10â€“03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P924.	0.4	3
166	Synaptic phosphorylated Î±-synuclein in dementia with Lewy bodies. <i>Brain</i> , 2017, 140, 3204-3214.	3.7	90
167	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. <i>Oncotarget</i> , 2017, 8, 104706-104716.	0.8	51
168	Cerebrospinal Fluid Anti-Amyloid-Î² Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 1-7.	1.2	43
169	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 539-546.	1.2	38
170	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in earlyâ€“stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016, 8, 466-476.	3.3	392
171	Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1327-1333.	1.2	7
172	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1489-1496.	1.2	14
173	White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 827-835.	1.2	17
174	O5â€“02â€“04: DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI): A PROSPECTIVE LONGITUDINAL BIOMARKER COHORT TO STUDY ALZHEIMER'S DISEASE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2016, 12, P380.	0.4	4
175	P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly. , 2016, 12, P807-P807.		0
176	O5-05-02: EVALUATION OF SYNAPTIC PROTEINS AS CEREBROSPINAL FLUID STAGE BIOMARKERS FOR ALZHEIMER'S DISEASE. , 2016, 12, P388-P388.		0
177	La prevenci3n de las demencias, un reto inmediato. <i>Revista Clinica Espanola</i> , 2016, 216, 483-484.	0.2	0
178	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2016, 132, 213-224.	3.9	83
179	Pittsburgh compound B imaging and cerebrospinal fluid amyloid-Î² in a multicentre European memory clinic study. <i>Brain</i> , 2016, 139, 2540-2553.	3.7	107
180	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 66.	4.4	9

#	ARTICLE	IF	CITATIONS
181	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A $\beta$ 42 Levels in Cognitively Normal Elderly. <i>Sleep</i> , 2016, 39, 2041-2048.	0.6	140
182	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 175-180.	1.1	13
183	Assessing the role of TUBA4A gene in frontotemporal degeneration. <i>Neurobiology of Aging</i> , 2016, 38, 215.e13-215.e14.	1.5	9
184	Use of amyloid-PET to determine cutpoints for CSF markers. <i>Neurology</i> , 2016, 86, 50-58.	1.5	54
185	Rare Variants in <i>PLD3</i> Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. <i>Human Mutation</i> , 2015, 36, 1226-1235.	1.1	23
186	Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 93-100.	1.2	35
187	Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S87-S98.	1.2	50
188	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 353-356.	0.6	8
189	P1-121: Comparison of different A $\beta$ -amyloid isoforms in CSF to detect amyloid pathology in cognitively normal subjects and patients with dementia. , 2015, 11, P387-P387.		0
190	Effect of REST on brain metabolism in the Alzheimer disease continuum. <i>Annals of Neurology</i> , 2015, 78, 661-662.	2.8	2
191	<i>APOE</i> -by-sex interactions on brain structure and metabolism in healthy elderly controls. <i>Oncotarget</i> , 2015, 6, 26663-26674.	0.8	92
192	La enfermedad de Alzheimer: El pr <sup>3</sup> ximo desafÃo para las personas con sÃndrome de Down. <i>Revista MÃdica Internacional Sobre El SÃndrome De Down</i> , 2015, 19, 35.	0.1	0
193	Evolving brain structural changes in PSEN1 mutation carriers. <i>Neurobiology of Aging</i> , 2015, 36, 1261-1270.	1.5	30
194	Cerebral Amyloid Angiopathy-Related Atraumatic Convexal Subarachnoid Hemorrhage: An ARIA before the Tsunami. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 710-717.	2.4	39
195	Correlates of cerebrospinal fluid levels of oligomeric- and total- $\alpha$ -synuclein in premotor, motor and dementia stages of Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 294-306.	1.8	85
196	Analysis of the <i>CHCHD10</i> gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. <i>Brain</i> , 2015, 138, e400-e400.	3.7	56
197	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. <i>Neurology</i> , 2015, 85, 626-633.	1.5	131
198	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015, 36, 2005.e15-2005.e22.	1.5	34

#	ARTICLE	IF	CITATIONS
199	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2018-2023.	1.5	75
200	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
201	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	3.8	501
202	PLD3 in non-familial Alzheimer's disease. <i>Nature</i> , 2015, 520, E3-E5.	13.7	58
203	Patterns of Performance on the Modified Cued Recall Test in Spanish Adults With Down Syndrome With and Without Dementia. <i>American Journal on Intellectual and Developmental Disabilities</i> , 2015, 120, 481-489.	0.8	16
204	Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?. <i>Cortex</i> , 2015, 73, 36-61.	1.1	201
205	P3-230: CSF $\beta$ -AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P715-P715.		0
206	IC-P-217: CSF $\beta$ -AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P117-P117.		0
207	Relationship Between $\beta$ -Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 157-167.	1.2	106
208	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , 2014, 6, 243ra86.	5.8	600
209	Cognitive functions in multiple sclerosis: impact of gray matter integrity. <i>Multiple Sclerosis Journal</i> , 2014, 20, 424-432.	1.4	47
210	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Human Molecular Genetics</i> , 2014, 23, 749-754.	1.4	98
211	Cerebrospinal fluid $\beta$ -amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2014, 76, 223-230.	2.8	110
212	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 684-691.	0.9	55
213	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	1.5	34
214	Posttranslational Nitro-Glycative Modifications of Albumin in Alzheimer's Disease: Implications in Cytotoxicity and Amyloid- $\beta$ Peptide Aggregation. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 643-657.	1.2	41
215	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 719-726.	1.2	53
216	P4-267: CORE ALZHEIMER'S DISEASE CSF BIOMARKERS IN DOWN SYNDROME. , 2014, 10, P882-P882.		2

#	ARTICLE	IF	CITATIONS
217	P4-320: NEUROPSYCHOLOGICAL ASSESSMENT OF ADULTS WITH DOWN SYNDROME USING THE CAMCOG-DS: A LONGITUDINAL COHORT STUDY. , 2014, 10, P903-P903.		3
218	P1-046: ROLE OF PLD3 RARE VARIANTS IN EUROPEAN SPORADIC ALZHEIMER'S DISEASE PATIENTS. , 2014, 10, P319-P320.		0
219	Comparison of 2 Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 469-476.	0.9	10
220	Rare Variants in Calcium Homeostasis Modulator 1 (CALHM1) Found in Early Onset Alzheimer's Disease Patients Alter Calcium Homeostasis. PLoS ONE, 2013, 8, e74203.	1.1	26
221	Evolving Brain Functional Abnormalities in PSEN1 Mutation Carriers: A Resting and Visual Encoding fMRI Study. Journal of Alzheimer's Disease, 2013, 36, 165-175.	1.2	19
222	Identifying Earlier Alzheimer's Disease: Insights from the Preclinical and Prodromal Phases. Neurodegenerative Diseases, 2012, 10, 158-160.	0.8	12
223	The amyloid- $\beta^2$ isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. Molecular Medicine Reports, 2012, 5, 1111-1115.	1.1	17
224	Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia. Neurobiology of Aging, 2012, 33, 1851.e17-1851.e19.	1.5	13
225	Distinct Functional Activity of the Precuneus and Posterior Cingulate Cortex During Encoding in the Preclinical Stage of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 517-526.	1.2	59
226	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. International Journal of Geriatric Psychiatry, 2012, 27, 127-134.	1.3	38
227	Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid A $\beta$ -Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas. Biological Psychiatry, 2011, 70, 183-190.	0.7	93
228	A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. Neuroscience Letters, 2011, 496, 40-42.	1.0	13
229	Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients. Journal of Alzheimer's Disease, 2011, 23, 319-326.	1.2	66
230	Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Research - Neuroimaging, 2011, 192, 140-146.	0.9	19
231	Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. Journal of Neural Transmission, 2011, 118, 259-262.	1.4	49
232	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease Families with PSEN1 Mutations. Neurodegenerative Diseases, 2011, 8, 202-207.	0.8	24
233	Increased Cortical Thickness and Caudate Volume Precede Atrophy in PSEN1 Mutation Carriers. Journal of Alzheimer's Disease, 2010, 22, 909-922.	1.2	136
234	Fatal worsening of late-onset cerebellar ataxia with neuronal intranuclear inclusions due to superimposed meningeal Rosai-Dorfman disease. Movement Disorders, 2008, 23, 1488-1490.	2.2	2

#	ARTICLE	IF	CITATIONS
235	A Nonsynonymous Mutation in PLCG2 Reduces the Risk of Alzheimer's Disease, Dementia with Lewy-Bodies and Frontotemporal Dementia, and Increases the Likelihood of Longevity. SSRN Electronic Journal, 0, , .	0.4	0